HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million. The company announced that HXP056 commenced its Phase I clinical trial in Chinese patients with wAMD in early July 2025. Patient recruitment for both the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages has been completed. Following four weeks of continuous dosing, the Dose-Limiting Toxicity (DLT) assessment and Pharmacokinetic (PK) data collection have been finalized. A preliminary efficacy evaluation is currently underway. In the fourth quarter of 2025, the company initiated a Phase II clinical dose expansion study. Notably, since March 9, HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list. Mainland investors who meet the eligibility criteria can now directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.